The work was led by Ellen A. Kearney of the University of Melbourne and the Burnet Institute, together with colleagues in Australia and Myanmar, including senior author Freya J. I. Fowkes. Their target was gSG6-P1, a peptide derived from the Anopheles gambiae Salivary Gland 6 protein. Antibodies against gSG6-P1 have been widely proposed as biomarkers of Anopheles biting exposure, but the authors note that most studies to date have been descriptive. What has been missing is a direct quantification of how an intervention changes antibody levels — both immediately and cumulatively over time — in a controlled trial setting.

The setting was the Greater Mekong Subregion, a hotspot of malaria transmission where elimination efforts face a stubborn problem: many infections occur among mobile and hard-to-reach populations, such as migrants and forest workers, who sleep outdoors or far from formal health services. In this context, personal protection tools like topical repellents are attractive because they do not depend on people being inside a bed net or a sprayed house. But measuring whether such tools actually reduce biting exposure across whole communities has been difficult, since mosquito counts and human landing catches are labour-intensive and imprecise.

To answer the question, the team drew on a stepped-wedge cluster randomised controlled trial in which personal repellent was distributed to 114 villages in Southeast Myanmar. In a stepped-wedge design, all clusters eventually receive the intervention, but the timing of the rollout is randomised, with villages crossing over from control to intervention in monthly blocks. This structure allows researchers to compare periods before and after intervention delivery within the same communities, while controlling for secular trends in transmission. The trial is registered in the Australian New Zealand Clinical Trials Registry and was approved by ethics committees in Myanmar and Australia, with informed consent collected from all participants or their guardians.

The serological engine of the study was a high-throughput enzyme-linked immunosorbent assay, or ELISA, run on an extraordinary 14,128 samples. Many of these were dried blood spots, a sampling format well suited to remote field settings because it requires only a finger-prick of blood that can be stored and transported without a cold chain. The assay quantified IgG antibodies specific to the gSG6-P1 peptide, expressed as optical density values, and classified participants as seropositive or seronegative depending on whether their signal exceeded a defined threshold.

The baseline picture was striking. Across the study population, antibody levels were generally high, with a median optical density of 2.1, and 59.9 percent of participants were seropositive for anti-gSG6-P1 IgG. In other words, roughly six in ten people carried measurable evidence of recent Anopheles biting. That prevalence alone confirms that the biomarker registers meaningful exposure in this setting, but the crucial question was whether the numbers would move when the repellent arrived.

Using generalised linear mixed-effects modelling, the researchers estimated both the instantaneous effect of repellent distribution — the change in antibody levels at the moment villages transitioned to the intervention — and a series of lagged effects designed to capture cumulative impact. The logic behind the lagged models is important: antibodies do not vanish overnight. If a repellent reduces biting, existing antibodies should decay gradually as the immune response wanes, so the effect of sustained repellent use should only emerge over subsequent months. The modelling therefore tested whether antibody levels fell in the months following distribution, treating the antibody response as a slowly turning dial rather than a switch.

The headline result was nuanced. Overall, there was no instantaneous effect of repellent on anti-gSG6-P1 IgG levels, with a mean difference of just 0.01 optical density units and a confidence interval spanning zero (95 percent CI −0.02 to 0.04; p = 0.583). When the team modelled delayed effects, the estimates pointed in the expected direction but remained statistically inconclusive: repellent distribution six months prior was associated with a 0.02-unit decrease in antibody levels (95 percent CI −0.07 to 0.03; p = 0.381). The picture sharpened, however, when the analysis was stratified by risk group. Migrants showed a statistically significant reduction in antibody levels at the six-month lag, with a mean difference of −0.10 (95 percent CI −0.20 to −0.001; p = 0.048), while forest dwellers showed a borderline reduction of −0.05 (95 percent CI −0.10 to 0.005; p = 0.075). Village residents, by contrast, showed no reduction at all (mean difference 0.02; 95 percent CI −0.04 to 0.08; p = 0.489).

That pattern makes biological sense. Migrants and forest dwellers are precisely the groups whose exposure is hardest to control with bed nets and indoor residual spraying, and who spend the most time in transmission hotspots. If a topical repellent works anywhere, it should work for people who apply it while exposed to intense outdoor biting. Yet the authors are careful to temper the interpretation: the magnitudes of the observed effects were small, and the confidence intervals were often wide, meaning the data cannot rule out effects ranging from negligible to modest. The study also did not find convincing changes in the odds of seropositivity, suggesting that the continuous antibody level may be a more sensitive metric than a binary seropositive classification in trials of this kind.

Even so, the study delivers something the field has lacked: empirical parameters on antibody kinetics in a real intervention trial. Knowing how quickly anti-gSG6-P1 IgG responds — and how slowly it decays — tells future trial designers how long they must wait after an intervention begins before antibody outcomes can be expected to move, and how large a sample they need to detect the change. The authors conclude that antibodies to Anopheles salivary proteins could serve as an informative outcome measure in vector-control trials, particularly in settings where conventional entomological monitoring is impractical. As malaria elimination programs in the Greater Mekong Subregion push into their endgame, tools that can quietly read a community’s biting exposure from a drop of dried blood may prove indispensable for knowing whether the last miles of the campaign are actually being won.

Subject of Research: Using anti-gSG6-P1 salivary antibodies as biomarkers of Anopheles biting exposure in a topical repellent trial

Article Title: Anopheles salivary antibody biomarker outcomes to assess the effectiveness of topical repellent in Southeast Myanmar

Article References: Kearney, E. A., Agius, P. A., O’Flaherty, K., Oo, W. H., Cutts, J. C., Htike, W., Da Silva Gonçalves, D., Thi, A., Aung, K. Z., Thu, H. K., Thein, M. M., Zaw, N. N., Htay, W. Y. M., Soe, A. P., Simpson, J. A., & Fowkes, F. J. I. (2026). Anopheles salivary antibody biomarker outcomes to assess the effectiveness of topical repellent in Southeast Myanmar. Parasites & Vectors. https://doi.org/10.1186/s13071-026-07694-6

Image Credits: AI Generated

DOI: 10.1186/s13071-026-07694-6

Keywords: malaria, Anopheles, salivary biomarkers, gSG6-P1, vector control, topical repellent, serology, ELISA, Myanmar, Greater Mekong Subregion, stepped-wedge trial, IgG antibodies

The trial, known as GAIN 2.0, evaluated an interdisciplinary intervention called Get going After concussIoN (GAIN) against enhanced usual care in adults aged 18 to 60 who were still suffering severe symptoms two to four months after their injury. The work, conducted across 16 of the 19 municipalities in the Central Denmark Region, was published in eClinicalMedicine. The researchers hypothesized that GAIN, delivered by therapists working in community settings rather than specialized hospital staff, would produce larger reductions in post-concussion symptoms three months after treatment compared with enhanced usual care alone.

The scientific rationale behind GAIN reflects a major shift in how researchers understand persistent post-concussion symptoms. While neurometabolic dysfunction and microstructural injury to the brain are real consequences of concussion, they cannot fully explain why some people recover and others do not. Instead, PPCS is increasingly understood through a biopsychosocial lens, in which biological, psychological, social, and environmental factors all shape the trajectory of recovery. Central to this model is the concept of illness perceptions—each patient’s subjective understanding of their symptoms and what they mean for the future.

Maladaptive illness perceptions can be remarkably destructive. A patient who catastrophizes about their symptoms, or who holds pessimistic expectations about recovery, may adopt behaviors that inadvertently perpetuate the problem. Some retreat into excessive rest and avoid any activity that provokes symptoms—a pattern known as fear-avoidance behavior. Others swing to the opposite extreme, engaging in so-called all-or-nothing behavior, pushing themselves hard when symptoms abate and then collapsing into prolonged recovery periods when symptoms inevitably return. These ideas align with the influential predictive coding model of symptom perception, which frames persistent physical symptoms as a potentially reversible disturbance in brain-body interaction and the experience of bodily signals.

GAIN was designed to interrupt this symptom-perpetuating cycle. Drawing on principles from third-wave cognitive behavioral therapy, the eight-week program supports patients in gradually returning to daily activities, with physical activity as a central treatment target. Participants are encouraged to be active every day with aerobic exercise of their choosing—walking, running, cycling, even gardening—beginning at an individualized starting level and increasing only gradually as tolerated. Importantly, a temporary worsening of symptoms is considered acceptable, provided it subsides by the next day. The original version of GAIN, tested in adolescents and young adults in a specialized hospital setting, had significantly reduced the risk of still suffering from PPCS three and twelve months after treatment ended.

The challenge for GAIN 2.0 was whether this success could survive the transition from a specialized hospital to ordinary municipal clinics staffed by physiotherapists and occupational therapists with limited prior experience. To answer this question, the researchers employed a stepped wedge cluster randomized design, one of the more elegant structures in clinical trial methodology. Five healthcare clusters in Central Denmark Region served as the units of randomization, and one cluster transitioned to delivering GAIN every three months in a randomly determined order. This design allowed therapists in each cluster to be trained shortly before their community began offering the intervention, while simultaneously reducing the risk that patients allocated to enhanced usual care would accidentally receive elements of GAIN.

Between May 2021 and November 2022, 310 participants were enrolled, with 170 allocated to GAIN plus enhanced usual care and 140 to enhanced usual care alone. Most participants were women, and more than half had higher education—consistent with evidence that both groups face elevated risk of developing PPCS. Roughly half of all participants were on full-time sick leave at enrollment, underscoring how disabling the condition can be. On average, participants entered the study nearly five months after their injury, with mean scores on the Rivermead Post-Concussion Symptoms Questionnaire around 36 out of a possible 64, well above the threshold for treatment-demanding symptoms.

The primary outcome was the change in RPQ total score from baseline to three-month follow-up. Here the results were nuanced. The group receiving GAIN did show greater symptom reduction, but the difference—2.4 points in the fully adjusted analysis—failed to reach statistical significance, with a confidence interval that included the possibility of no difference. Yet at the end of the eight-week intervention itself, the effect was striking and robust: GAIN participants had improved by roughly 5.5 points more than controls, a highly significant difference that diminished over subsequent months. It appears the intervention accelerated recovery, but the advantage eroded as the control group caught up over time.

Where GAIN truly shone was in its predefined treatment targets. At three-month follow-up, the GAIN group showed substantially larger reductions in maladaptive illness perceptions, excessive rest, all-or-nothing behavior, and fear avoidance. Illness worry, measured by the Whiteley-6 questionnaire, also improved significantly more in the GAIN group. Participants reported high satisfaction with the intervention, and 69 percent described their general health as improved compared with before treatment. Only 5 percent reported minor adverse effects such as temporary fatigue or symptom flares, and no serious adverse events occurred. Post-hoc analysis also revealed that the treatment effect varied significantly depending on whether participants had a psychiatric diagnosis at some point before their concussion, suggesting that patient complexity matters.

Why did the effect on symptom severity itself fade? The researchers point to what trial scientists call the voltage drop—the tendency for a treatment’s efficacy to shrink when scaled up from ideal conditions to real-world delivery. The municipal therapists received only a two-day training course before delivering GAIN, and audio recordings revealed that strategies targeting maladaptive symptom-perpetuating perceptions—a core component of the therapy—were applied in only 57 percent of sessions. Participants in GAIN 2.0 were also more complex than those in the original trial, being older on average and more likely to carry prior psychiatric or functional somatic diagnoses. Moreover, an eight-week, low-dose intervention may simply be insufficient for highly symptomatic patients, many of whom still exceeded the treatment threshold when the program ended. The researchers suggest that extended treatment periods, booster sessions, and enhanced therapist training could strengthen long-term outcomes, and they call for future studies to examine whether GAIN improves participation in everyday life even when symptom scores alone do not dramatically change.

Subject of Research: A stepped wedge cluster randomised trial testing the GAIN interdisciplinary intervention against enhanced usual care for reducing persistent post-concussion symptoms in adults.

Article Title: Interdisciplinary intervention (GAIN) vs. enhanced usual care for reducing severe post-concussion symptoms in adults 2–4 months post-injury: A stepped wedge cluster randomised controlled trial

Article References: Hellemose, L. A., Thastum, M. M., Stabel, H. H., Odgaard, L., Rask, C. U., Silverberg, N. D., Skandsen, T., Rytter, H. M., Nygaard, C., Eggertsen, P. P., Pedersen, C. B., & Nielsen, J. F. (2026). Interdisciplinary intervention (GAIN) vs. enhanced usual care for reducing severe post-concussion symptoms in adults 2–4 months post-injury: A stepped wedge cluster randomised controlled trial. eClinicalMedicine, Article 104243. https://doi.org/10.1016/j.eclinm.2026.104243

Image Credits: AI Generated

DOI: 10.1016/j.eclinm.2026.104243

Keywords: concussion, persistent post-concussion symptoms, GAIN intervention, cognitive behavioral therapy, stepped wedge trial, illness perceptions, fear avoidance, mild traumatic brain injury, municipal rehabilitation, Denmark, physical activity, randomised controlled trial

The study, conducted by the Neo-MILK Consortium and published in BMC Medicine, was a stepped-wedge cluster-randomized trial carried out in fifteen German Level I neonatal intensive care units between April 2022 and March 2024. In a stepped-wedge design, all participating units eventually receive the intervention, but the timing of the switch is randomized, so that at any given moment some units are providing the new program while others are still delivering standard care. This approach is particularly well suited to hospital-level interventions that cannot easily be withheld from individual patients, and it allowed the researchers to compare outcomes before and after implementation within the same institutions while controlling for temporal trends. The trial was registered in the German Clinical Trials Register under DRKS00025058 and was designed as a hybrid type 1 effectiveness-implementation study, meaning that its primary aim was to test whether the intervention worked, with a secondary focus on how well it could be put into practice.

The intervention itself, known as Neo-MILK, combined two complementary strategies. The first was structured lactation support: standardized counselling for mothers beginning before delivery where possible, multilingual written and digital materials, and a mobile application that gave parents guidance and encouragement throughout what is often an exhausting and emotionally fraught hospital stay. The second component was the establishment of human donor milk banking, which allows pasteurized milk from screened donor mothers to be given to infants whose own mothers cannot yet supply enough milk. Alongside these clinical elements, the researchers deployed a set of implementation strategies aimed at the hospitals themselves, including video-based staff training, written guidelines, commitment nudges designed to prompt medical staff to prioritize human milk feeding, and practical assistance in setting up donor milk banks where none existed.

The primary outcome was the proportion of very low birth weight infants discharged home fed exclusively on their mother’s own milk. Among the 1,627 infants enrolled, 831 in the intervention phase and 796 in the control phase, the intervention raised exclusive mother’s own milk feeding at discharge by 11 percentage points, from a baseline of 43 percent, with a 95 percent confidence interval of 3.0 to 19.0 percentage points and a p-value of 0.007. In parallel, the proportion of infants fed exclusively on formula declined correspondingly, suggesting that the program did not merely reshuffle feeding categories but genuinely converted formula-dependent infants to human milk feeding. For a population in which every milliliter of mother’s milk is associated with reduced risks of necrotizing enterocolitis, infections, and other life-threatening complications, an eleven-point gain achieved through organizational change rather than new drugs or devices is a striking result.

Equally important is what the trial did not find. Rates of clinical complications and the length of hospital stay showed no differences between the intervention and control periods, indicating that the push toward human milk feeding did not come with unintended harms or delayed discharges. The researchers also prespecified subgroup analyses to determine whether the intervention worked equally well across the spectrum of vulnerability, comparing infants with birth weights below 1,000 grams against those at or above that threshold, and infants with high illness severity, defined by a Clinical Risk Index for Babies score of 11 or greater, against those with lower scores. Here the results were more sobering: no significant effects emerged in extremely low birth weight infants or in the highest-risk group, a pattern that the authors interpret as a signal that the most fragile babies may need additional, tailored strategies beyond the standard support package.

Because the trial was designed as a hybrid effectiveness-implementation study, the team went well beyond the primary clinical endpoint and systematically measured how the intervention was received and sustained. Acceptability, appropriateness, and feasibility were all rated highly by participating units, suggesting that the program fit reasonably well into existing workflows. Fidelity was sufficient overall, although not uniform: prepartal counselling, the earliest and arguably most critical touchpoint, was delivered as intended in 71 percent of cases, leaving room for improvement in reaching mothers before birth. The establishment of human donor milk banks proved to be the most variable element, with banks successfully created at only 40 percent of the participating sites, a finding that underscores how much organizational, regulatory, and logistical work stands behind what sounds like a simple idea of sharing breast milk. On the positive side, sustainability indicators were promising, with 61 percent of staff reporting that the new practices had been integrated into routine care by the end of the study.

The economic evaluation added a dimension that is often missing from neonatal nutrition research. Using time-driven activity-based costing, a method that maps every staff activity and resource involved in delivering care, combined with a budget impact analysis, the researchers estimated the financial consequences of rolling out the program nationally. In the base-case scenario, the analysis suggested potential net savings, meaning that the costs of counselling, training, and donor milk banking could be offset by reductions elsewhere in the care pathway. While the authors are careful to frame this as a scenario-dependent projection rather than a guarantee, the finding matters for health systems weighing whether to fund such programs at scale, particularly in Germany where statutory health insurers collaborated in the study and where the German Innovation Fund of the Federal Joint Committee financed the work under grant 01NVF19027.

The trial’s design deserves attention from anyone following the methodology of complex health interventions. By randomizing the order in which the fifteen units crossed over to the intervention, the stepped-wedge approach preserved the ethical appeal of eventually offering the program to everyone while still generating a controlled comparison. The intention-to-treat analysis framework, the use of intracluster correlation coefficients to account for the clustering of outcomes within hospitals, and the prespecification of subgroups all reflect a rigor that strengthens confidence in the headline finding. At the same time, the variability in donor milk bank uptake across sites illustrates a persistent challenge in implementation science: an intervention is only as strong as the organizational soil in which it is planted, and units differ widely in staffing, culture, and infrastructure.

For clinicians and policymakers, the message of the Neo-MILK trial is twofold. First, structured lactation support combined with donor milk banking is an effective, safe, and potentially cost-saving way to increase exclusive mother’s own milk feeding at discharge for very low birth weight infants, moving a substantial fraction of babies from formula to human milk without increasing complications or length of stay. Second, the work is not finished: the absence of measurable benefit in the smallest and sickest infants, the incomplete delivery of prepartal counselling, and the uneven establishment of donor milk banks all point to the need for ongoing organizational support and strategies tailored to the highest-risk families. As neonatal units around the world grapple with how to raise human milk feeding rates, this German trial provides both a tested blueprint and an honest account of where that blueprint still falls short.

Subject of Research: A stepped-wedge cluster-randomized trial evaluating structured lactation support and human donor milk banking in German neonatal intensive care units

Article Title: Effectiveness of structured lactation support and human donor milk banking in German NICUs: a stepped-wedge cluster-randomized trial

Article References: Köberlein-Neu, J., Dymek, N. G., Zimmer, V., Bommhardt, T., Stirner, A. K., Güldenring, I., Ohnhäuser, T., Wiesen, D., Dresbach, T., Scholten, N., & Neo-MILK Consortium/collaborators (2026). Effectiveness of structured lactation support and human donor milk banking in German NICUs: a stepped-wedge cluster-randomized trial. BMC Medicine. https://doi.org/10.1186/s12916-026-05211-1

Image Credits: AI Generated

DOI: 10.1186/s12916-026-05211-1

Keywords: lactation support, human donor milk, very low birth weight infants, neonatal intensive care, stepped-wedge trial, mother's own milk feeding, donor milk banking, neonatology, implementation science, health economics, BMC Medicine, Neo-MILK